Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen A Harrison

Showing results (181-190 of 318) with videos related to

Pageof 32
Sort By:
Journal of Hepatology|July 2, 2020
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trialsBeth A Davison, Stephen A Harrison, Gad Cotter, et al.
Alimentary Pharmacology & Therapeutics|January 17, 2023
Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosisMazen Noureddin, Zachary Goodman, Dean Tai, et al.
Hepatology (Baltimore, Md.)|July 18, 2018
Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United StatesDonghee Kim, Andrew A Li, Brandon J Perumpail, et al.
Journal of Hepatology|February 13, 2021
A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitisStephen A Harrison, Mustafa R Bashir, Kyoung-Jin Lee, et al.
Hepatology (Baltimore, Md.)|October 28, 2020
NAFLD: Reporting Histologic Findings in Clinical PracticeElizabeth M Brunt, David E Kleiner, Danielle H Carpenter, et al.
Hepatology International|January 30, 2019
Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016Donghee Kim, Won Kim, Adeyinka C Adejumo, et al.
Plos One|December 16, 2017
Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acidWonbeak Yoo, Donjeta Gjuka, Heather L Stevenson, et al.
Expert Opinion on Drug Safety|September 5, 2012
Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studiesPatrick Marcellin, Stuart K Roberts, K Rajender Reddy, et al.
Journal of Hepatology|May 24, 2023
NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation studyStephen A Harrison, Vlad Ratziu, Jeremy Magnanensi, et al.
The American Journal of Gastroenterology|August 12, 2021
Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver DiseaseStephen A Harrison, Seth J Baum, Nadege T Gunn, et al.
Pageof 32

Showing results (181-190 of 318) with videos related to

Sort By:
Pageof 32
Journal of Hepatology|July 2, 2020
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trialsBeth A Davison, Stephen A Harrison, Gad Cotter, et al.
Alimentary Pharmacology & Therapeutics|January 17, 2023
Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosisMazen Noureddin, Zachary Goodman, Dean Tai, et al.
Hepatology (Baltimore, Md.)|July 18, 2018
Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United StatesDonghee Kim, Andrew A Li, Brandon J Perumpail, et al.
Journal of Hepatology|February 13, 2021
A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitisStephen A Harrison, Mustafa R Bashir, Kyoung-Jin Lee, et al.
Hepatology (Baltimore, Md.)|October 28, 2020
NAFLD: Reporting Histologic Findings in Clinical PracticeElizabeth M Brunt, David E Kleiner, Danielle H Carpenter, et al.
Hepatology International|January 30, 2019
Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016Donghee Kim, Won Kim, Adeyinka C Adejumo, et al.
Plos One|December 16, 2017
Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acidWonbeak Yoo, Donjeta Gjuka, Heather L Stevenson, et al.
Expert Opinion on Drug Safety|September 5, 2012
Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studiesPatrick Marcellin, Stuart K Roberts, K Rajender Reddy, et al.
Journal of Hepatology|May 24, 2023
NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation studyStephen A Harrison, Vlad Ratziu, Jeremy Magnanensi, et al.
The American Journal of Gastroenterology|August 12, 2021
Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver DiseaseStephen A Harrison, Seth J Baum, Nadege T Gunn, et al.
Pageof 32